3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Terminated
2
Unknown
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
993
Neoplasms
852
Carcinoma, Non-Small-Cell Lung
844
Prostatic Neoplasms
528
Neoplasm Metastasis
501
Leukemia, Myeloid, Acute
489
Melanoma
456
Colorectal Neoplasms
447
Multiple Myeloma
441
Lung Neoplasms
421
Pancreatic Neoplasms
353
Recurrence
350
Lymphoma
350
Ovarian Neoplasms
341
Lymphoma, Non-Hodgkin
329
Leukemia
324
Leukemia, Lymphocytic, Chronic, B-Cell
302
Precursor Cell Lymphoblastic Leukemia-Lymphoma
271
Carcinoma, Renal Cell
256
Head and Neck Neoplasms
246
Brain Neoplasms
245
Carcinoma, Hepatocellular
234
Glioblastoma
232
Squamous Cell Carcinoma of Head and Neck
231
Myelodysplastic Syndromes
230
Lymphoma, Large B-Cell, Diffuse
228
Lymphoma, Follicular
219
Colonic Neoplasms
191
Stomach Neoplasms
182
Rectal Neoplasms
175
Interventions
brolucizumab
1
aflibercept
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Interventional
×
Macular Degeneration
×
Clear all
NCT02626377
2023-10-23
ICE
Centre Hospitalier Universitaire de Besancon
Phase NA
Terminated
186 enrolled
NCT03710564
2023-01-30
MERLIN
Novartis
Phase 3
Terminated
535 enrolled
14 charts